How Glucagon Protection Breaks Down Early in Type 1 Diabetes

When blood sugar drops dangerously low, the healthy body has a built-in emergency response: the pancreas releases glucagon, a hormone that tells the liver to release stored glucose. This counterregulatory system acts like a safety net, preventing severe hypoglycemia.

But children newly diagnosed with Type 1 diabetes lack this protection from the very start. In a new study called GLUREDIA, researchers compared 22 children and adolescents with newly diagnosed Type 1 diabetes to eight healthy relatives during controlled low-blood-sugar tests. The healthy group showed strong glucagon surges when blood sugar fell. The children with Type 1 diabetes showed essentially no glucagon response at all—even when their blood sugar dropped deeper than the healthy children's did.

What happened next was surprising. Researchers retested the children at 6, 12, and 18 months after diagnosis using the same controlled low-blood-sugar procedure.

The glucagon response didn't simply stay broken. At 6 months, it temporarily improved—a statistically significant recovery. But by 12 months, the response had disappeared again. And by 18 months, something unexpected occurred: glucagon was actually suppressed when blood sugar fell, the opposite of what should happen.

This shifting pattern suggests that glucagon dysfunction in children with Type 1 diabetes is not a one-time event at diagnosis, but rather an evolving process. The reasons why glucagon protection waxes and wanes remain unclear and warrant further investigation.

Impaired glucagon response is known to be a major contributor to hypoglycemia risk in Type 1 diabetes. When the body cannot reliably release glucagon during low blood sugar, dangerous episodes become more likely and harder to prevent with insulin management alone.

Until now, most research on broken glucagon counterregulation came from studies of adults. This study is one of the first to carefully map when and how this problem develops in children—from the moment of diagnosis forward. That timeline matters for clinical care.

The researchers also collected data on continuous glucose monitoring metrics and circulating biomarkers. Identifying which children lose glucagon protection earliest, and what biological markers predict that loss, could eventually help doctors flag which patients face the highest risk and may need more intensive monitoring or different management strategies.

The GLUREDIA study is ongoing, and this report focuses on the first 18 months of follow-up. The researchers are analyzing additional biomarkers that might explain why glucagon dysfunction appears, improves, and worsens in these patterns. Understanding the biology behind these changes could open new avenues for protecting children with Type 1 diabetes from severe lows.

For now, this research underscores an important reality: the physiological defenses against hypoglycemia in newly diagnosed children are fragile from day one. Better awareness of this vulnerability may help families, care teams, and researchers work together to prevent the most dangerous episodes.

Source: BMJ open diabetes research & care. Evidence type: PubMed indexed literature. Type1Cure is an information and intelligence hub, not a medical advice service. This article summarizes published research and does not provide diagnosis, treatment, or personal medical guidance. Always talk to your own care team before changing anything about your Type 1 diabetes management.